Payment overview · 2025
General Payments
$350.39
15 reported records · 12 companies
Healthcare provider profile · identity verified
James Edward Vandruff, DO
Allopathic & Osteopathic Physicians|Family Medicine · PAYSON, AZ · NPI 1710481411
Verified facts
What the public records show
CMS Open Payments records show James Edward Vandruff, DO received $350.39 in general payments during 2025 across 15 reported records.
Tactile Systems Technology Inc accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $79.09 | 22.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $48.43 | 13.8% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $38.57 | 11.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$28.58 | 8.2% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $25.30 | 7.2% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $25.02 | 7.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.93 | 6.5% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.13 | 5.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.52 | 5.0% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.02 | 4.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.07 | 4.6% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $11.73 | 3.4% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $350.39 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $79.09 | 2 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $79.09 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $48.43 | 2 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $38.57 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $28.58 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $25.30 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc. | $25.02 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.52 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $11.73 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 73 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
73 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 480 | 158 |
| Lisinopril | Lisinopril | 415 | 126 |
| Levothyroxine Sodium | Levothyroxine Sodium | 413 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 335 | 99 |
| Losartan Potassium | Losartan Potassium | 258 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 232 | 69 |
| Gabapentin | Gabapentin | 230 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 190 | 52 |
| Metformin Hcl | Metformin Hcl | 183 | 60 |
| Omeprazole | Omeprazole | 180 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 151 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 133 | 36 |
| Trazodone Hcl | Trazodone Hcl | 133 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 129 | 42 |
| Sertraline Hcl | Sertraline Hcl | 125 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 122 | 39 |
| Potassium Chloride | Potassium Chloride | 113 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 37 |
| Simvastatin | Simvastatin | 108 | 33 |
| Eliquis | Apixaban | 101 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 90 | 21 |
| Jardiance | Empagliflozin | 87 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 25 |
| Allopurinol | Allopurinol | 81 | 27 |
| Montelukast Sodium | Montelukast Sodium | 80 | 19 |
| Tramadol Hcl | Tramadol Hcl | 78 | 33 |
| Alprazolam | Alprazolam | 77 | 21 |
| Atenolol | Atenolol | 75 | 19 |
| Furosemide | Furosemide | 74 | 27 |
| Ozempic | Semaglutide | 74 | 20 |
| Carvedilol | Carvedilol | 73 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 69 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 14 |
| Famotidine | Famotidine | 61 | 18 |
| Synthroid | Levothyroxine Sodium | 61 | 17 |
| Azithromycin | Azithromycin | 59 | 45 |
| Xarelto | Rivaroxaban | 59 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 17 |
| Mupirocin | Mupirocin | 49 | 25 |
| Prednisone | Prednisone | 49 | 26 |
| Meloxicam | Meloxicam | 47 | 16 |
| Estradiol | Estradiol | 46 | 15 |
| Lorazepam | Lorazepam | 46 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | 19 |
| Glipizide Er | Glipizide | 44 | 13 |
| Fenofibrate | Fenofibrate | 43 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 12 |
| Alendronate Sodium | Alendronate Sodium | 42 | 13 |
| Baclofen | Baclofen | 42 | 21 |
| Ondansetron Odt | Ondansetron | 42 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 12 |
| Finasteride | Finasteride | 40 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 12 |
| Bupropion Xl | Bupropion Hcl | 38 | 12 |
| Acyclovir | Acyclovir | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 12 |
| Glipizide | Glipizide | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 16 |
| Azelastine Hcl | Azelastine Hcl | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | 12 |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Ibuprofen | Ibuprofen | 31 | 14 |
| Pregabalin | Pregabalin | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 16 |
| Clonazepam | Clonazepam | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 20 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Modafinil | Modafinil | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $350.39 · 15 records | Tactile Systems Technology Inc | AIRSUPRA, Cologuard Collection Kit, Flexitouch Plus, LEQVIO, LifeVest, MINIMED 780G, Nimbl, PANZYGA, TRELEGY ELLIPTA, Tascenso ODT, ZENPEP, Zilbrysq | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error